Commercializing Your First Cell Or Gene Therapy (CGT): Five Best Practices For Planning

By Joe DePinto, head of cell, gene, and advanced therapies, McKesson

Bringing a cell or gene therapy (CGT) to market presents a unique set of challenges that differ significantly from traditional drug development. The personalized nature of these therapies means that each one carves out its own distinct patient, product, and reimbursement journey. Factors such as whether the therapy is cell-based or gene-based, autologous or allogeneic, and how it's administered all contribute to different market access needs.

Early and thorough commercialization planning is therefore not just advisable, but essential, ideally beginning as early as Phase I/II studies. Continue reading to explore five essential practices for effective CGT commercialization.